000 03357naa a22005177i 4500
001 UMUN-OA-20261005-MLS-052
003 local
005 20261005174905.0
006 m o d
007 cr||||||||||||
008 261005s2020 xx o u000 0 eng d
024 7 _a10.1186/s12931-020-01570-2
_2doi
035 _a(local)EuropePMC:PMC7677848
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aGrégoire Ruffenach
_eauthor.
245 1 0 _aPulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights. /
_cGrégoire Ruffenach; Jason Hong; Mylène Vaillancourt [and others].
264 1 _a[Place of publication not identified] :
_bBMC,
_c2020.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aPulmonary hypertension (PH) developing secondarily in pulmonary fibrosis (PF) patients (PF-PH) is a frequent co-morbidity. The high prevalence of PH in PF patients is very concerning since the presence of PH is a strong predictor of mortality in PF patients. Until recently, PH was thought to arise solely from fibrotic destruction of the lung parenchyma, leading to hypoxic vasoconstriction and loss of vascular bed density. Thus, potential cellular and molecular dysregulation of vascular remodeling as a driver of PF-PH has been under-investigated. The recent demonstrations that there is no correlation between the severity of the fibrosis and development of PH, along with the finding that significant vascular histological and molecular differences exist between patients with and without PH have shifted the etiological paradigm of PF-PH. This review aims to provide a comprehensive translational overview of PH in PF patients from clinical diagnosis and outcome to the latest understanding of the histology and molecular pathophysiology of PF-PH.
540 _aCreative Commons Attribution. See the linked licence for the applicable terms.
_uhttp://creativecommons.org/licenses/by/4.0/
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Medical Laboratory Science.
650 4 _aPulmonary fibrosis
650 4 _aPulmonary hypertension
650 4 _aVascular diseases
653 _aB. Sc. Medical Laboratory Science
653 _aUMUN open access collection
653 _ahistopathology
655 4 _aReview articles.
700 0 _aJason Hong
_eauthor.
700 0 _aMylène Vaillancourt
_eauthor.
700 0 _aLejla Medzikovic
_eauthor.
700 0 _aMansoureh Eghbali
_eauthor.
773 0 _tRespiratory research
_gVol. 21, no. 1, (2020), pages/article 303
_x1465-9921
856 4 0 _uhttps://europepmc.org/articles/PMC7677848
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC7677848
_qlocal
942 _n0
999 _c1194
_d1194